Anti-infective drug development requires model-informed approaches to optimise dosing across ages. While paediatric pharmacokinetic studies often extrapolate from adult population pharmacokinetic (PopPK) models, physiological differences and variations in data richness can limit direct extrapolation. Ceftazidime-avibactam, an antibacterial combination licensed across all ages, provides a strong test case for developing robust extrapolation methods. This study therefore […]
